Global issues in drug development for Alzheimer's disease

Alzheimer's and Dementia

Volumn 7, Issue 2, 2011, Pages 197-207

  Doody, Rachelle S ^a   Cole, Patricia E ^b   Miller, David S ^c   Siemers, Eric ^d   Black, Ronald ^e   Feldman, Howard ^f   Schindler, Rachel ^e   Graham, Stephen ^g   Heath, Theresa ^h   Khachaturian, Ara S ⁱ   Evans, Rebecca ^e   Carrillo, Maria C ⁱ  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Imagepace   (United States)

^c UNITED BIOSOURCE CORPORATION   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e PFIZER INC   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

^g Forest Pharmaceuticals Inc   (United States)

^h Bio Analytical Research Corporation   (United States)

ⁱ ALZHEIMER'S ASSOCIATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; BIOETHICS; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DRUG DEVELOPMENT; GOVERNMENT REGULATION; MEDICAL RESEARCH; PRIORITY JOURNAL;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; DRUG DISCOVERY; HUMANS;

EID: 79952728896     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2011.01.001     Document Type: Conference Paper

References (35)

1. Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, Schulman KA. Ethical and scientific implications of the globalization of clinical research. N Engl J Med 2009;360:816-23.
2. Edland SD, Edmond JA, Aisen PS, Petersen RC. NIA-funded Alzheimer Centers are more efficient than commercial clinical recruitment sites for conduction secondary prevention trials of Dementia. Alzheimer Dis Assoc Disord 2010;24:159-64.
3. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's disease neuroimaging initiative (ADNI). Alzheimer Dement 2005;1:55-6.
4. Weiner MW, Aisen PS, Jack CR, Jaqust WJ, Trojanowski JQ, Shaw L, et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimer Dement 2010;6:202-11.
5. Iwatsubo T. Japanese Alzheimer's disease neuroimaging initiative: present status and future. Alzheimer Dement 2010;6:297-9.
6. Frisoni GB. Alzheimer's disease neuroimaging initiative in Europe. Alzheimer Dement 2010;6:280-5.
7. Ellis KA, Rowe CC, Villemagne VL, Martins RN, Masters CL, Salvado O, et al. Addressing population aging and Alzheimer's disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer's disease neuroimaging initiative. Alzheimer Dement 2010;6:291-6.
8. Snyder PJ, Papp KV, Bartkowick J, Jackson CE, Doody R. Commentary on "Roadmap for the prevention of dementia II. Leon Thal symposium 2008." Recruitment of participants for Alzheimer's disease clinical trials: the role of trust in caregivers, clinical researchers, regulatory authorities and industry sponsors. Alzheimer Dement 2009;5:122-7.
9. Doody R. Commentary on "A roadmap for the prevention of dementia II: Leon Thal symposium 2008." Centers of Excellence in Alzheimer's disease: it is time to better integrate patient care and clinical research to improve the prevention and treatment of AD. Alzheimer Dement 2009;5:133-6.
10. Trojanowski J, Arnold S, Karlawish J, Brunden K, Cary M, Davatzikos C, et al. Design of comprehensive Alzheimer's disease centers to address unmet national needs. Alzheimer Dement 2010;6:150-5.
11. Prince M, Wimo A. World Alzheimer Report 2010: the global economic impact of dementia; introduction, methods and results and discussion. Available at: http://www.alz.co.uk/research/files/World AlzheimerReport2010.pdf.
12. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-7. (Pubitemid 41797645)
13. Llibre Rodriguez JJ, Ferri CP, Acosta D, Guerra M, Huang Y, Jacob KS, et al. Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey. Lancet 2008;372:464-74.
14. Zhang ZX, Zahner GE, Román GC, Liu J, Hong Z, Qu QM, et al. Dementia subtypes in China: prevalence in Beijing, Xian, Shanghai, and Chengdu. Arch Neurol 2005;62:447-53. (Pubitemid 40349481)
15. Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo- controlled phase III study. Dement Geriatr Cogn Disord 2010;30:131-46.
16. Henley DB, May PC, Dean RA, Siemers ER. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin Pharmacother 2009;10:1657-64.
17. Zhang ZX, Chen X, Liu XH, Tang MN, Zhao HH, Jue QM, et al. A caregiver survey in Beijing, Xi'an, Shanghai and Chengdu: health services status for the elderly with dementia. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2004;26:116-21.
18. Wimo A, Prince M.World Alzheimer report 2010: the global impact of dementia. Alzheimer's Disease International 2010.
19. Prince MJ, Acosta D, Castro-Costa E, Jackson J, Shaji KS. 2009 packages of care for dementia in low- and middle-income countries. PLoS Med 2006;6: e1000176.
20. Miller D, Samuelson P, Foulds K, Wesnes KA, Moya G. Miller identifying capable raters for global Alzheimer's disease clinical trials: challenges and potential solutions. In: 14th International Psychogeriatric Association (IPA) Congress; September 2009; Montreal, Quebec, Canada.
21. Miller DS, Bartko JJ, Connor DJ. Administration and scoring variability among ADAS-Cog raters. In: 11th International Conference on Alzheimer's Disease (ICAD); July 2008; Chicago, IL.
22. McNamara C, Samuelson P, Miller DS, Jones A, Moya G, Butler A. Global Surveillance Program Monitoring Raters' Administration and Scoring of the ADAS-Cog. In: 22nd European College of Neuropsychopharmacology (ECNP) Congress; September 2009; Istanbul, Turkey.
23. Mattsson N, Zetterberg H, Blennow K. Lessons from multicenter studies on CSF biomarkers for Alzheimer's disease. Int J Alzheimer Dis 2010;1:55-66.
24. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasmabiomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-44.
25. International Conference on harmonization 1996 good clinical practices [EU, MHLW, FDA. International Conference on Harmonization Guideline for Good Clinical Practice; 1997].
26. Dixon JR Jr. The International Conference on Harmonization Good Clinical Practice guideline. Qual Assur 1998;6:65-74.
27. Chang JJ, Zu J, Fan D. A comparative method of evaluating quality of international clinical studies in China: analysis of site visit reports of the clinical research operations and monitoring center. Contemp Clin Trials 2008;29:654-62.
28. Nundy S, Gulhati CM. A new colonialism? - Conducting clinical trials in India. N Engl J Med 2005;352:1633-6. (Pubitemid 40530229)
29. Annas GJ. Globalized clinical trials and informed consent. N Engl J Med 2009;360:2050-3.
30. White L, Petrovitch H, Ross GW, Masaki HK, Abbott RD, Teng EL, et al. Prevalence of dementia in older Japanese-American men in Hawaii: the Honolulu-Asia aging study. JAMA 1996;276:955-60. (Pubitemid 26318224)
31. Hendri HC, Murrell J, Gao S, Unverzagt FW, Ogunniyi A, Hall KS. International studies in dementia with particular emphasis on populations of African origin. Alzheimer Dis Assoc Disord 2006;20(3 Suppl. 2):S42-6.
32. International ethical guidelines for biomedical research involving human subjects. Prepared by the Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization; 2002. Available at: http://www.fda.gov/ICEDI/ EnforcementActions/ BioresearchMonitoring/default.htm.
33. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/ CFRSearch.cfm?fr=312.120.
34. Mohs RC, Cohen L. Alzheimer's Disease Assessment Scale (ADAS). Psychopharmacol Bull 1998;24:627-8.
35. Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, The NTB. a neuropsychological test battery for use in Alzheimer's disease clinical trials. Arch Neurol 2007;64:1323-9. (Pubitemid 47403089)